Literature DB >> 8890821

Marked expression of plasma brain natriuretic peptide is a special feature of hypertrophic obstructive cardiomyopathy.

K Nishigaki1, M Tomita, K Kagawa, T Noda, S Minatoguchi, H Oda, S Watanabe, N Morita, K Nakao, H Fujiwara.   

Abstract

OBJECTIVES: We examined whether plasma brain natriuretic peptide levels are abnormally elevated in hypertrophic obstructive cardiomyopathy compared with other cardiac diseases.
BACKGROUND: We previously reported that plasma brain and atrial natriuretic peptide levels were elevated in hypertrophic cardiomyopathy.
METHODS: We compared plasma concentrations of brain and atrial natriuretic peptide and hemodynamic and echocardiographic data in 50 patients with hypertrophic obstructive cardiomyopathy (n = 15, mean [+/-SD] intraventricular pressure gradient 37 +/- 16 mm Hg), hypertrophic nonobstructive cardiomyopathy (n = 15), aortic stenosis (n = 10, mean pressure gradient 41 +/- 18 mm Hg) and hypertensive heart disease (n = 10, mean systolic/diastolic blood pressure 203 +/- 16/108 +/- 11 mm Hg, respectively) and 10 normal subjects.
RESULTS: Plasma brain natriuretic peptide levels were higher in the hypertrophic obstructive cardiomyopathy group (397.1 +/- 167.8 pg/ml*) than in the hypertrophic nonobstructive cardiomyopathy (60.0 +/- 48.1 pg/ml*), hypertensive heart disease (53.9 +/- 31.4 pg/ml*), aortic stenosis (75.4 +/- 54.3 pg/ml*) and normal groups (9.8 +/- 6.4 pg/ml [*p < 0.05 vs. normal group, p < 0.05 vs. hypertrophic obstructive cardiomyopathy group]). Although plasma atrial natriuretic peptide levels were higher in the hypertrophic obstructive cardiomyopathy group than the other patient groups, the brain/atrial natriuretic peptide ratio in the hypertrophic obstructive cardiomyopathy group was higher (4.5 +/- 2.3) than those in the other three patient groups (1.1 to 1.4) and the normal group (0.7 +/- 0.5). Left ventricular end-diastolic pressure and left ventricular end-diastolic volume index were similar among the four patient groups. The interventricular septal thickness and the ratio of interventricular septal thickness to left ventricular posterior wall thickness were similar between the hypertrophic obstructive and nonobstructive cardiomyopathy groups.
CONCLUSIONS: Abnormal elevations of plasma brain natriuretic peptide levels are difficult to explain on the basis of hemodynamic and echocardiographic data and are a special feature of hypertrophic obstructive cardiomyopathy.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8890821     DOI: 10.1016/S0735-1097(96)00277-X

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  10 in total

1.  Degree and distribution of left ventricular hypertrophy as a determining factor for elevated natriuretic peptide levels in patients with hypertrophic cardiomyopathy: insights from cardiac magnetic resonance imaging.

Authors:  Jeong Rang Park; Jin-Oh Choi; Hye Jin Han; Sung-A Chang; Sung-Ji Park; Sang-Chol Lee; Yeon Hyeon Choe; Seung Woo Park; Jae K Oh
Journal:  Int J Cardiovasc Imaging       Date:  2011-04-24       Impact factor: 2.357

2.  Amount of left ventricular hypertrophy determines the plasma N-terminal pro-brain natriuretic peptide level in patients with hypertrophic cardiomyopathy and normal left ventricular ejection fraction.

Authors:  Seon Woon Kim; Seung Woo Park; Seong-Hoon Lim; Sung Uk Kwon; Yu Jeong Choi; Man Ki Park; Sang-Chol Lee; Sang Hoon Lee; Jeong Euy Park; Eun-Seok Jeon
Journal:  Clin Cardiol       Date:  2006-04       Impact factor: 2.882

3.  Value of plasma B type natriuretic peptide measurement for heart disease screening in a Japanese population.

Authors:  M Nakamura; H Endo; M Nasu; N Arakawa; T Segawa; K Hiramori
Journal:  Heart       Date:  2002-02       Impact factor: 5.994

4.  Higher copeptin levels are associated with worse outcome in patients with hypertrophic cardiomyopathy.

Authors:  Irfan Sahin; Baris Gungor; Berk Ozkaynak; Fatih Uzun; Suat Hayri Küçük; Ilhan Iker Avci; Ender Ozal; Burak Ayça; Sukru Cetın; Ertugrul Okuyan; Mustafa Hakan Dinckal
Journal:  Clin Cardiol       Date:  2016-10-21       Impact factor: 2.882

5.  The association between brain natriuretic peptide and tissue Doppler parameters in children with hypertrophic cardiomyopathy.

Authors:  Taliha Öner; Rahmi Özdemir; Filiz Hazan; Cem Karadeniz; Önder Doksoz; Murat Muhtar Yilmazer; Timur Meşe; Vedide Tavli
Journal:  Bosn J Basic Med Sci       Date:  2016-01-01       Impact factor: 3.363

6.  Variability of NT-proBNP and its relationship with inflammatory status in patients with stable essential hypertension: a 2-year follow-up study.

Authors:  Esther Roselló-Lletí; Jose R Calabuig; Pedro Morillas; Raquel Cortés; Luis Martínez-Dolz; Luis Almenar; Jose R González-Juanatey; Catheline Lauwers; Antonio Salvador; Manuel Portolés; Vicente Bertomeu; Miguel Rivera
Journal:  PLoS One       Date:  2012-02-23       Impact factor: 3.240

7.  Prognostic values of highly sensitive cardiac troponin T and B-type natriuretic peptide for clinical features in hypertrophic obstructive cardiomyopathy: a cross-sectional study.

Authors:  Shunichi Nakamura; Hitoshi Takano; Junya Matsuda; Daigo Chinen; Mitsunobu Kitamura; Koji Murai; Kuniya Asai; Masahiro Yasutake; Morimasa Takayama; Wataru Shimizu
Journal:  BMJ Open       Date:  2014-09-17       Impact factor: 2.692

8.  Total Clinical Course and Autopsy Findings of Left Ventricular Outflow Tract Obstruction Due to Sigmoid Septum: Histologically Proven Isolated Basal Septal Hypertrophy.

Authors:  Keisuke Kawai; Hiroyuki Sengoku; Hiroyuki Ishihara; Tomotoshi Akematsu; Masakazu Nanahoshi; Hirotoshi Hariki; Minoru Hasokawa; Ken-Ichi Hirata; Hiroshi Yamabe
Journal:  Intern Med       Date:  2017-08-01       Impact factor: 1.271

9.  Association of NT-proBNP and hs-cTnT with Imaging Markers of Diastolic Dysfunction and Focal Myocardial Fibrosis in Hypertrophic Cardiomyopathy.

Authors:  Céleste Chevalier; Miriam Wendner; Anna Suling; Ersin Cavus; Kai Muellerleile; Gunnar Lund; Paulus Kirchhof; Monica Patten
Journal:  Life (Basel)       Date:  2022-08-16

10.  Correlations between cardiac troponin I and nonsustained ventricular tachycardia in hypertrophic obstructive cardiomyopathy.

Authors:  Limin Liu; Shangyu Liu; Lishui Shen; Bin Tu; Zhicheng Hu; Feng Hu; Lihui Zheng; Ligang Ding; Xiaohan Fan; Yan Yao
Journal:  Clin Cardiol       Date:  2020-08-18       Impact factor: 2.882

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.